These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28829813)

  • 41. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
    Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
    BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Raman spectroscopy for diagnosing EGFR mutation status in lung adenocarcinoma.
    Wang L; Zhang Z; Huang L; Li W; Lu Q; Wen M; Guo T; Fan J; Wang X; Zhang X; Fang J; Yan X; Ni Y; Li X
    Analyst; 2014 Jan; 139(2):455-63. PubMed ID: 24303521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.
    Long C; Li K; Liu Z; Zhang N; Xing X; Xu L; Gai F; Che N
    Cancer Med; 2023 Apr; 12(7):7982-7991. PubMed ID: 36621813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of
    Jin J; He J; Yan X; Zhao Y; Zhang H; Zhuang K; Wen Y; Gao J
    Am J Transl Res; 2022; 14(8):5605-5613. PubMed ID: 36105060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
    Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS
    Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
    Zhang H; Liu D; Li S; Zheng Y; Yang X; Li X; Zhang Q; Qin N; Lu J; Ren-Heidenreich L; Yang H; Wu Y; Zhang X; Nong J; Sun Y; Zhang S
    J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of icotinib on advanced lung adenocarcinoma patients with sensitive
    Chen HF; Lei L; Wu LX; Li XF; Zhang QX; Pan WW; Min YH; Zhu YC; Du KQ; Wang M; Wang WX; Xu CW
    Transl Cancer Res; 2019 Dec; 8(8):2858-2863. PubMed ID: 35117043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.
    Suzawa K; Yamamoto H; Ohashi K; Hashida S; Tomida S; Kubo T; Maki Y; Soh J; Tsukuda K; Kiura K; Miyoshi S; Toyooka S
    Oncol Rep; 2017 May; 37(5):3100-3106. PubMed ID: 28405680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies.
    Qu YG; Zhang Q; Pan Q; Zhao XD; Huang YH; Chen FC; Chen HL
    Int J Nanomedicine; 2014; 9():5771-8. PubMed ID: 25525358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.
    Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH
    Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer.
    Lam DC; Tam TC; Lau KM; Wong WM; Hui CK; Lam JC; Wang JK; Lui MM; Ho JC; Ip MS
    Clin Lung Cancer; 2015 Nov; 16(6):507-13. PubMed ID: 26239567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings.
    Kawahara A; Fukumitsu C; Taira T; Abe H; Takase Y; Murata K; Yamaguchi T; Azuma K; Ishii H; Takamori S; Akiba J; Hoshino T; Kage M
    Cancer Cytopathol; 2015 Oct; 123(10):620-8. PubMed ID: 26235264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
    Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
    Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.
    Reck M; Hagiwara K; Han B; Tjulandin S; Grohé C; Yokoi T; Morabito A; Novello S; Arriola E; Molinier O; McCormack R; Ratcliffe M; Normanno N
    J Thorac Oncol; 2016 Oct; 11(10):1682-9. PubMed ID: 27468938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma.
    Wang Z; Cheng G; Han X; Mu X; Zhang Y; Cui D; Liu C; Zhang L; Fan Z; Ma L; Yang L; Di J; Cram DS; Shi Y; Liu D
    J Mol Diagn; 2017 Jan; 19(1):169-181. PubMed ID: 27870944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.